TGFB1 and neoplasm: We propose increased L1 ORF1p expression in tumour cells as a candidate predictive biomarker worthy of consideration in ongoing clinical trials, of single agent TGFβ inhibitors, or those mono/combination approaches impacting the inflammatory/immune environment.